Buzz Before Opening: Gilat Satellite Networks Ltd. (NASDAQ:GILT), ANSYS, Inc. (NASDAQ:ANSS), Synthetic Biologics Inc. (NYSEMKT:SYN)
Dallas, Texas, 09/24/2014 (ustrademedia) – Gilat Satellite Networks Ltd. (NASDAQ:GILT) today announced an order for its Satcom-On-The-Move terminals from Myanmar-based Terabit Wave Co. Ltd. An order is placed for a Myanmar governmental agency and also includes vehicle-mounted satellite antennas, tactical satcom units and related equipment. An order is placed for a SkyEdge II with anticipated rollout during 3Q14 and 4Q14. Gilat Satellite Networks Ltd. (NASDAQ:GILT) CEO, ErezAntebi expressed that the company’s terminals addressed Terabit Wave’s specifications for their light weight, compact design and also provided ease of operation and are quick to dismantle. Terabit Wave won the order through a ‘competitive bidding process’ wherein several local and global solution providers also applied.
ANSYS, Inc. (NASDAQ:ANSS) today announced to sign an agreement with Modelon to transform product development by speeding time-to-market, reducing late stage integration failures and product development costs. Modelon’s behavioral modeling tools and solutions with the company’s system simulation platform and embedded software will enable users to explore product designs. Such an integrated, multi-disciplinary approach will allow companies to decrease their reliance on costly physical prototyping and arrive at better designs earlier. Chief Product Officer at ANSYS, Inc. (NASDAQ:ANSS), Walid Abu-Hadba expressed that the agreement will enable the users to fully explore their product behavior as a complete system, supporting them to build more innovative products faster-than-ever.
Synthetic Biologics Inc. (NYSEMKT:SYN) will convene the 21st Annual NewsMakers in the Biotech Industry on Friday, September 26, 2014 at 08:00 a.m. in New York City. The event will showcase 48 publicly listed Biotech companies selected independently on the basis of key clinical, commercial and regulatory milestones. Hundreds of investment professionals, licensing and business development executives have pre-registered for the event. The selected companies have more than 35 products in total, which are on the market or are approved. These companies are collectively conducting more than 240 clinical trials across cardiovascular diseases, cancer, inflammation, infectious disease and autoimmune diseases.